Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity
Top Cited Papers
Open Access
- 15 October 2000
- journal article
- Published by American Society of Hematology in Blood
- Vol. 96 (8) , 2717-2722
- https://doi.org/10.1182/blood.v96.8.2717
Abstract
There is evidence that the total cellular content of placental cord blood (PCB) grafts is related to the speed of engraftment, though the total nucleated cell (TNC) dose is not a precise predictor of the time of neutrophil or platelet engraftment. It is important to understand the reasons for the quantitative association and to improve the criteria for selecting PCB grafts by using indices more precisely predictive of engraftment. The posttransplant course of 204 patients who received grafts evaluated for hematopoietic colony-forming cell (CFC) content among 562 patients reported previously were analyzed using univariate and multivariate life-table techniques to determine whether CFC doses predicted hematopoietic engraftment speed and risk for transplant-related events more accurately than the TNC dose. Actuarial times to neutrophil and platelet engraftment were shown to correlate with the cell dose, whether estimated as TNC or CFC per kilogram of recipient's weight. CFC association with the day of recovery of 500 neutrophils/μL, measured as the coefficient of correlation, was stronger than that of the TNC (R = −0.46 and −0.413, respectively). In multivariate tests of speed of platelet and neutrophil engraftment and of probability of posttransplantation events, the inclusion of CFC in the model displaced the significance of the high relative risks associated with TNC. The CFC content of PCB units is associated more rigorously with the major covariates of posttransplantation survival than is the TNC and is, therefore, a better index of the hematopoietic content of PCB grafts.Keywords
This publication has 27 references indexed in Scilit:
- Using at least 5×106/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantationBone Marrow Transplantation, 1999
- Outcomes among 562 Recipients of Placental-Blood Transplants from Unrelated DonorsNew England Journal of Medicine, 1998
- Outcome of Cord-Blood Transplantation from Related and Unrelated DonorsNew England Journal of Medicine, 1997
- Placental Blood as a Source of Hematopoietic Stem Cells for Transplantation into Unrelated RecipientsNew England Journal of Medicine, 1996
- Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG‐CSF): an analysis of factors correlating with the tempo of engraftment after transplantationBritish Journal of Haematology, 1994
- Can cord blood be used?Nature, 1989
- Donor marrow progenitors (CFU-Mix, BFU-E) and (CFU-GM) and haemopoietic engraftment following HLA matched sibling bone marrow transplantationLeukemia Research, 1987
- Lack of correlation between nucleated bone marrow cell dose, marrow CFU-GM dose or marrow CFU-E dose and the rate of HLA-identical sibling marrow engraftmentBritish Journal of Haematology, 1985
- No influence of number of donor CFU-GM on granulocyte recovery in bone marrow transplantation for acute leukemiaAnnals of Hematology, 1985
- Marrow Transplantation for Treatment of Aplastic AnemiaNew England Journal of Medicine, 1977